ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on Monday, December 8, 2025, at 3:20 p.m. ET. Investors interested in arranging a meeting with company ...

Core Insights - Supernus Pharmaceuticals, Inc. is participating in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, where CEO Jack A. Khattar will engage in a fireside chat [1][2] Company Overview - Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases [3][4] - The company's diverse neuroscience portfolio includes approved treatments for ADHD, dyskinesia in Parkinson's disease, hypomobility in Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [4]

Core Insights - Supernus Pharmaceuticals, Inc. is participating in the 2025 Jefferies Global Healthcare Conference in London on November 17, 2025, where CEO Jack A. Khattar will engage in a fireside chat [1] - The company focuses on developing and commercializing products for central nervous system (CNS) diseases [3][4] Company Overview - Supernus Pharmaceuticals specializes in treatments for various CNS disorders, including ADHD, Parkinson's disease-related dyskinesia, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [4] - The company is also developing a range of novel product candidates targeting CNS disorders [4] Investor Relations - Investors interested in meeting with company management during the conference can contact the Jefferies conference coordinator [2] - A live audio webcast of the presentation will be available, with an archived replay accessible for 60 days post-conference [2]

Core Insights - Supernus Pharmaceuticals, Inc. is participating in multiple investor conferences in September 2025, showcasing its focus on central nervous system (CNS) diseases [1][2][3] Conference Details - The company will present at the Cantor Global Healthcare Conference on September 3, 2025, at 8:00 a.m. ET in New York [1] - The Wells Fargo Healthcare Conference is scheduled for September 4, 2025, at 8:45 a.m. ET in Everett, MA [2] - The TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit will take place virtually on September 18, 2025, at 10:40 a.m. ET [3] Webcast Information - A live audio webcast of the presentations will be available on the Supernus Pharmaceuticals website, with archived replays accessible for 60 days post-conference [4] Company Overview - Supernus Pharmaceuticals specializes in developing and commercializing products for CNS diseases, with a diverse portfolio that includes treatments for ADHD, Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [5][6]

Core Insights - Supernus Pharmaceuticals, Inc. is participating in the 2025 Jefferies Global Healthcare Conference on June 4, 2025, where CEO Jack A. Khattar will engage in a fireside chat [1] - The company focuses on developing and commercializing products for central nervous system (CNS) diseases [3][4] Company Overview - Supernus Pharmaceuticals specializes in treatments for CNS diseases, including ADHD, dyskinesia in Parkinson's disease, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [4] - The company is also developing new potential treatments for epilepsy, depression, and other CNS disorders [4] Conference Details - Investors can arrange meetings with company management during the conference by contacting the Jefferies conference coordinator [2] - A live audio webcast of the presentation will be available, with an archived replay accessible for 60 days post-conference [2]